Home   About the Journal  Editorial Board  Online Journal   Publishing Ethics   Contact Us  Chinese Version
You are here:Home => Online Journal => Vol.36 No.11 => Discussions by experts =>
Treatment of hepatorenal syndrome: Vasoconstriction or vasodilation?
文章发布日期:2020年10月22日  来源:  作者:李晓芸,华静  点击次数:4481次  下载次数:134次
Adjust font size:Small regular big

【Abstract】:Hepatorenal syndrome (HRS) is a serious complication that occurs in patients with decompensated cirrhosis or acute/chronic liver failure. The main pathological features of HRS include marked peripheral vasodilation and strong renal vasoconstriction, with rapid progression, unsatisfactory treatment response, and poor prognosis. Vasoconstrictors are mainly used in the pharmacotherapy for HRS, and at present, terlipressin combined with albumin is the first-line treatment method for HRS. Some drugs with a renal vasodilatory effect also show a potential therapeutic effect. This article reviews the latest research advances in the role and clinical application of vasoactive drugs in the treatment of HRS.
【Key words】:hepatorenal syndrome; vasoconstrictor agents; therapeutics

Mail address: Editorial Office of Journal of Clinical Hepatology, 519 Dongminzhu Street, Changchun, Jilin, China Postal code: 130061 Tel:+86-431-88782542/3542
Journal of Clinical Hepatology Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号